John Kennedy - CONMED President
| CNMD Stock | USD 67.98 0.76 1.13% |
President
Mr. John E. Kennedy is Vice President and General Manager U.S. Endoscopic Technologies of the Company. He joined the Company in September 2012 as Vice President and General Manager, Visualization and Endomechanical. In January 2015, Mr. Kennedy became Vice President and General Manager, U.S. Endoscopic Technologies. Prior to joining the Company, Mr. Kennedy served as President and Chief Executive Officer of Viking Systems, Inc. from January 2010 to September 2012. Mr. Kennedy had formerly served as President and Chief Operating Officer of Viking Systems, Inc. from October 2007 to December 2009. Prior to October 2007, Mr. Kennedy was the President of the Vision SystemsGroup at Viking Systems, Inc. From January 1997 to September 2007, Mr. Kennedy held various executive positions with Vista Medical Technologies, Inc. Prior to joining Vista Medical Technologies, Inc., Mr. Kennedy held various positions in Manufacturing, Quality Engineering and Product Development at Smith Nephew Endoscopy from 1984 through January 1997. Prior to 1984, he held various engineering positions at Honeywells ElectroOptics and Avionics divisions since 2015.
| Age | 66 |
| Tenure | 9 years |
| Address | 11311 Concept Boulevard, Largo, FL, United States, 33773-4908 |
| Phone | 727 392 6464 |
| Web | https://www.conmed.com |
CONMED Management Efficiency
The company has return on total asset (ROA) of 0.0368 % which means that it generated a profit of $0.0368 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1025 %, meaning that it created $0.1025 on every $100 dollars invested by stockholders. CONMED's management efficiency ratios could be used to measure how well CONMED manages its routine affairs as well as how well it operates its assets and liabilities. At present, CONMED's Return On Assets are projected to slightly decrease based on the last few years of reporting. At present, CONMED's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 83.5 M, whereas Net Tangible Assets are projected to grow to (642.7 M).Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Troy Villarreal | HCA Holdings | N/A | |
| Sandra Morgan | HCA Holdings | 57 | |
| Christopher Howard | Acadia Healthcare | 57 | |
| Dan Miller | HCA Holdings | N/A | |
| Kathleen Whalen | HCA Holdings | 57 | |
| Kathryn Torres | HCA Holdings | 57 | |
| Robert Waterman | HCA Holdings | 66 | |
| Timothy McManus | HCA Holdings | 52 | |
| John Steele | HCA Holdings | 62 | |
| Christopher Wyatt | HCA Holdings | 43 | |
| Alan Yuspeh | HCA Holdings | 67 | |
| Jana Davis | HCA Holdings | 57 | |
| Ravi Chari | HCA Holdings | 51 | |
| Jeff Cohen | HCA Holdings | 49 | |
| Heather Rohan | HCA Holdings | N/A | |
| Juan Vallarino | HCA Holdings | 54 | |
| Robert Oliva | Novo Integrated Sciences | 60 | |
| Brian Cook | HCA Holdings | N/A | |
| Mark Kimbrough | HCA Holdings | N/A | |
| Paul Paslick | HCA Holdings | 61 | |
| Arnold Moore | HCA Holdings | 60 | |
Management Performance
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0368 |
CONMED Leadership Team
Elected by the shareholders, the CONMED's board of directors comprises two types of representatives: CONMED inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CONMED. The board's role is to monitor CONMED's management team and ensure that shareholders' interests are well served. CONMED's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CONMED's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Beyer, President of CONMED International | ||
| John Ferrell, Executive Resources | ||
| Laverne Council, Independent Director | ||
| Todd Garner, Chief Financial Officer, Executive Vice President | ||
| David Murray, President Electrosurgery | ||
| Shanna Cottiosmanski, Executive Vice President - Information Technology & CIO | ||
| Nathan Folkert, Vice President General Manager - Orthopedics business | ||
| Brent Lalomia, Executive Affairs | ||
| John Workman, Independent Director | ||
| Charles Farkas, Independent Director | ||
| Barbara Schwarzentraub, Independent Director | ||
| Terence Berge, Vice President and Corporate Controller | ||
| Peter Shagory, Executive Vice President - Strategy and Corporate Development | ||
| Heather Cohen, Executive Vice President - Human Resources, Secretary | ||
| Mark Snyder, Executive Vice President - Operations & Business Systems | ||
| Stanley Peters, Vice President and General Manager - U.S. Advanced Surgical | ||
| Jerome Lande, Independent Director | ||
| Daniel Jonas, Executive Vice President - Legal Affairs, General Counsel, Secretary | ||
| Jo Golden, Independent Director | ||
| David Bronson, Independent Director | ||
| Brian Concannon, Independent Director | ||
| Johonna Pelletier, Treasurer and Vice President - Tax | ||
| Curt Hartman, Chairman of the Board, President, Chief Executive Officer | ||
| Wilfredo RuizCaban, Executive Vice President - Quality Assurance, Regulatory Affairs and Operations | ||
| Dirk Kuyper, Independent Director | ||
| Luke Pomilio, CFO, Principal Accounting Officer and Executive VP of Fin. | ||
| Stanley III, President Technologies | ||
| Sarah Oliker, Assistant General Counsel, Assistant Secretary | ||
| Daniel Esq, Special Secretary | ||
| Mark Tryniski, Independent Chairman of the Board | ||
| John Kennedy, Vice President and General Manager - U.S. Endoscopic Technologies | ||
| Gregory Jones, Executive VP of Quality Assurance and Regulatory Affairs | ||
| Martha Aronson, Lead Independent Director |
CONMED Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CONMED a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.1 | ||||
| Return On Asset | 0.0368 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.1 % | ||||
| Current Valuation | 3.03 B | ||||
| Shares Outstanding | 30.8 M | ||||
| Shares Owned By Insiders | 0.54 % | ||||
| Shares Owned By Institutions | 99.46 % | ||||
| Number Of Shares Shorted | 846.97 K | ||||
| Price To Earning | 188.03 X |
Pair Trading with CONMED
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CONMED position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CONMED will appreciate offsetting losses from the drop in the long position's value.Moving together with CONMED Stock
| 0.62 | AHG | Akso Health Group | PairCorr |
Moving against CONMED Stock
| 0.74 | SNDA | Sonida Senior Living | PairCorr |
| 0.74 | TNDM | Tandem Diabetes Care Financial Report 1st of May 2024 | PairCorr |
| 0.66 | GCTK | GlucoTrack | PairCorr |
| 0.66 | TLIS | Talis Biomedical Corp | PairCorr |
| 0.59 | JYNT | Joint Corp Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to CONMED could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CONMED when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CONMED - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CONMED to buy it.
The correlation of CONMED is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CONMED moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CONMED moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CONMED can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for CONMED Stock analysis
When running CONMED's price analysis, check to measure CONMED's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CONMED is operating at the current time. Most of CONMED's value examination focuses on studying past and present price action to predict the probability of CONMED's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CONMED's price. Additionally, you may evaluate how the addition of CONMED to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is CONMED's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CONMED. If investors know CONMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CONMED listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 9.567 | Dividend Share 0.8 | Earnings Share 2.61 | Revenue Per Share 41.046 | Quarterly Revenue Growth 0.057 |
The market value of CONMED is measured differently than its book value, which is the value of CONMED that is recorded on the company's balance sheet. Investors also form their own opinion of CONMED's value that differs from its market value or its book value, called intrinsic value, which is CONMED's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CONMED's market value can be influenced by many factors that don't directly affect CONMED's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CONMED's value and its price as these two are different measures arrived at by different means. Investors typically determine if CONMED is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CONMED's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.